

LABORATORY CORP OF AMERICA HOLDINGS  
Form 8-K  
December 07, 2010

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

December 2, 2010  
(Date of earliest event reported)

LABORATORY CORPORATION OF  
AMERICA HOLDINGS  
(Exact Name of Registrant as Specified in its Charter)

Delaware  
(State or other jurisdiction of  
Incorporation)

1-11353  
(Commission File Number)

13-3757370  
(I.R.S. Employer Identification No.)

358 South Main Street,  
Burlington, North Carolina  
(Address of principal executive offices)

27215  
(Zip Code)

336-229-1127  
(Registrant's telephone number including  
area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Laboratory Corporation of America ® Holdings (LabCorp ®)(NYSE:LH) announced that on December 2, 2010, N. Anthony Coles, M.D. was appointed to its Board of Directors, effective January 1, 2011. Dr. Coles will also serve on the Quality and Compliance Committee of the Board of Directors. Dr. Coles will be entitled to receive compensation for his service on the Board of Directors consistent with LabCorp's director compensation program, as described under the heading Director Compensation in LabCorp's proxy statement for its 2010 Annual Meeting of Stockholders as filed with the Securities and Exchange Commission on April 1, 2011, which description is incorporated in this Form 8-K by reference. Dr. Coles, 50, is President, CEO and a member of the board of Onyx Pharmaceuticals, Inc., located in Emeryville, California.

Item 7.01 Regulation FD Disclosure

On December 7, 2010, LabCorp issued the press release attached to this Form 8-K as Exhibit 99.1 announcing the appointment of Dr. Coles.

---

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 Press Release issued by the Company on December 7, 2010

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

LABORATORY CORPORATION OF AMERICA HOLDINGS  
Registrant

By: /s/ F. SAMUEL EBERTS III  
F. Samuel Eberts III  
Chief Legal Officer and Secretary

December 7, 2010

---

EXHIBIT INDEX

99.1 Press Release issued by the Company on December 7, 2010

---

---